An Observational Study of Thrombolysis Outcomes in Wake-Up Ischemic Stroke Patients
Stroke 44:427-431, Manawadu, D.,et al, 2013
Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age
JNNP 82:712-717, Bhatnagar, P.,et al, 2011
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009
Hemorrhage After Thrombolytic Therapy for Stroke: The Clinically Relevant Number Needed to Harm
Stroke 38:2279-2283, Saver,J.L., 2007
Thrombolysis for Acute Stroke with Special Emphasis on the Very Old:Experience From a Single Dutch Centre
JNNP 77:375-377,288, van Oostenbrugge,R.J.,et al, 2006
The Stroke-Thrombolytic Predictive Instrument: A Predictive Instrument for Intravenous Thrombolysis in Acute Ischemic Stroke
Stroke 37:2957-2962,2865, Kent,D.M.,et al, 2006
Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?
Stroke 37:2963-2969, Kent,D.M.,et al, 2006
Diagnosis and Treatment of Ischemic Stroke
Am J Med 106:211-221, Alberts,M.J., 1999
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
Lithium Therapy in Kleine-Levin Syndrome
Neurol 85:1655-1662, Leu-Semenescu, S.,et al, 2015
Should Statins be Paused or Discontinued After Thrombolysis or Acute Intracerebral Hemorrhage? No!
Stroke 44:1472-1476, Scheitz, J.F.,et al, 2013
Elderly Patients are at Higher Risk for Poor Outcomes after Intra-Arterial Therapy
Stroke 43:2356-2361, Chandra, R.V.,et al, 2012
Statin Use Following Intracerebral Hemorrhage
Arch Neurol 68:573-579, Westover, M.B.,et al, 2011
Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy
NEJM 365:285-287, Egan, A.,et al, 2011
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Bleeding Risk Analysis in Stroke Imaging Before ThromboLysis (BRASIL): Pooled Analysis of T2*-Weighted Magnetic Resonance Imaging Data From 570 Patients
Storke 38:2738-2744, Fiehler,J.,et al, 2007
Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005
The Risk-Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Genseng, Echinacea, Saw Palmetto, and Kava
Ann Int Med 136:42-53, Ernst,E., 2002
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000